Flagship explainer
What drives RIGEL PHARMACEUTICALS INC’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| $367M | FY2025 |
| |
| Income before tax | $122M | FY2025 |
|
| Operating income | $125M | FY2025 |
|
| $294M | FY2025 |
| |
| Ending assets | $514M | FY2025 |
|
| Beginning assets | $164M | FY2024 |
|
| $391M | FY2025 |
| |
| $3.3M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001034842-26-000015
- SEC filingFiling detailsAccession 0001558370-25-002169